BioCentury | Oct 6, 2020
Product Development

Reversing the impact of COVID-19 on oncology clinical trials

The COVID-19 pandemic has harmed thousands of cancer patients by delaying or postponing clinical trials for new anticancer agents in various indications. These patients, whose lives depend on finding new...
BioCentury | Aug 25, 2020
Deals

Reverse merger offers Yumanity faster, less risky path to NASDAQ

...gained $0.06 to $1.36 on Monday.TARGETSSCD1 —Stearoyl-CoA...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Fat metabolism enzyme DECR1 as castration-resistant prostate cancer target

...volume. Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (Tokyo:4503) market Xtandi for prostate cancer. TARGET/MARKER/PATHWAY: 2,4-dienoyl-CoA...
BioCentury | May 13, 2020
Product Development

Arvinas unveils first efficacy signal for targeted protein degradation, points to opportunity in resistant cancers

...androgen receptor levels in tumor biopsies. Arvinas also disclosed adverse events in patients taking the HMG-CoA...
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...Shafique Virani as chief corporate development officer. He was CEO of Navire Pharma Inc. and CoA...
BioCentury | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

...CEO-in-residence at BridgeBio Pharma Inc. (NASDAQ:BBIO) and CEO of Navire Pharma Inc. and BridgeBio subsidiary CoA...
BioCentury | Aug 28, 2019
Distillery Therapeutics

Lipid metabolism regulator ACBP identified as target in obesity

...fat mass and hepatosteatosis. Also in the mice, systemic ACBP knockout reduced weight gain. TARGET/MARKER/PATHWAY: Acyl-CoA...
BioCentury | Jul 10, 2019
Company News

Yumanity’s Coles picks Merrimack, Onyx alum Peters to lead company to the clinic

...proteins. It plans to kick off a Phase I trial of its lead molecule targeting stearoyl-CoA...
...a new project, yet. The appointment takes effect on Sept 3. Lauren Martz, Associate Editor Yumanity Therapeutics LLC Stearoyl-CoA...
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

...treat pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia, which gives the HMG-CoA...
...Ltd. Kowa Co. Ltd. Merck & Co. Inc. Sino Biopharmaceutical Ltd. TrakCel Ltd. Fungal cytochrome P450 C-14 alpha demethylase (fungal CYP51) HMG-CoA...
BioCentury | Jun 19, 2019
Financial News

Coenzyme A company Comet debuts with $28.5M series A

...conditions and neurometabolic diseases. For instance, he said, myelin sheath formation is dependent on acetyl CoA...
Items per page:
1 - 10 of 467